- Home
- EML vs IPHA Comparison
EML vs IPHA Comparison
Compare EML & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EML
- IPHA
- Stock Information
- Founded
- EML 1858
- IPHA 1999
- Country
- EML United States
- IPHA France
- Employees
- EML N/A
- IPHA N/A
- Industry
- EML Industrial Machinery/Components
- IPHA Biotechnology: Pharmaceutical Preparations
- Sector
- EML Consumer Discretionary
- IPHA Health Care
- Exchange
- EML Nasdaq
- IPHA Nasdaq
- Market Cap
- EML 144.5M
- IPHA 160.1M
- IPO Year
- EML N/A
- IPHA 2019
- Fundamental
- Price
- EML $23.25
- IPHA $2.03
- Analyst Decision
- EML
- IPHA Strong Buy
- Analyst Count
- EML 0
- IPHA 1
- Target Price
- EML N/A
- IPHA $11.00
- AVG Volume (30 Days)
- EML 13.4K
- IPHA 6.5K
- Earning Date
- EML 08-05-2025
- IPHA 09-11-2025
- Dividend Yield
- EML 1.91%
- IPHA N/A
- EPS Growth
- EML N/A
- IPHA N/A
- EPS
- EML N/A
- IPHA N/A
- Revenue
- EML $271,440,503.00
- IPHA $20,831,349.00
- Revenue This Year
- EML $1.56
- IPHA $209.83
- Revenue Next Year
- EML $7.00
- IPHA $83.15
- P/E Ratio
- EML $11.06
- IPHA N/A
- Revenue Growth
- EML 8.15
- IPHA N/A
- 52 Week Low
- EML $19.06
- IPHA $1.29
- 52 Week High
- EML $35.03
- IPHA $3.51
- Technical
- Relative Strength Index (RSI)
- EML 48.92
- IPHA 61.03
- Support Level
- EML $23.21
- IPHA $1.71
- Resistance Level
- EML $23.80
- IPHA $2.10
- Average True Range (ATR)
- EML 0.56
- IPHA 0.07
- MACD
- EML -0.07
- IPHA 0.04
- Stochastic Oscillator
- EML 32.56
- IPHA 82.50
About EML Eastern Company (The)
The Eastern Co manages industrial businesses that design, manufacture, and sell engineered solutions to industrial markets. The company manages the financial, operational, and strategic performance of its businesses to increase cash generation, operating earnings, and long-term shareholder value. It operates in the United States and Other Countries and generates the majority of its revenue from the United States.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.